This indicator measures progress of treatment coverage among people living with chronic HBV, towards the 2030 hepatitis elimination goals.
Definition:
Number of people diagnosed with chronic hepatitis B and eligible for treatment who have initiated antiviral therapy by the end of the reporting period
Not all people diagnosed with chronic hepatitis B are eligible for treatment. Treatment eligibility differs across countries and regions and should be defined in accordance with current WHO guidelines or regional or national guidelines.
Disaggregation:
By country and WHO region
Method of measurement
Country-reported data: The indicator is compiled from routine national programme, surveillance, drug supply management systems, clinical or health information system records.
Data should cover the reporting year and the geographical and population scope reported by the country. Countries should describe whether the data are national or subnational, which sectors and facilities are included, and whether individual-level deduplication or record linkage is used.
Modelled estimates: Where complete country-reported data are unavailable, WHO may produce a country-calibrated estimate using available programme data, epidemiological evidence, demographic data and other relevant inputs. The modelled estimate is intended to provide a coherent value for the specified reference year and may not equal a value reported directly by the country.
Method of estimation:
HBV model structure (PRoGReSs model): the HBV model uses a dynamic mathematical framework that estimates annual HBV prevalence and incidence by stage of liver disease, age and sex using disease progression and mortality (all-cause and liver-related) rates. The model integrates demographic profiles, vaccination coverage (including timely birth dose and three-dose infant
series), prevention measures such as hepatitis B immune globulin (HBIG) and maternal antiviral prophylaxis, HBV diagnosis and treatment schedules, and established HBV epidemiological parameters. Perinatal, early childhood and horizontal transmission are modelled using age-specific hepatitis B surface antigen (HBsAg) prevalence together with available prevention-coverage data. This allows the model to reflect both historical and current programme performance.
Method of estimation of global and regional aggregates:
Regional estimates are calculated as the sum of country level data in each of the WHO regions.
Preferred data sources:
Facility-based treatment registers or drug supply management systems
Unit of Measure:
Number
Expected frequency of data dissemination:
Every two years
Expected frequency of data collection:
Continuous at country level reported every two years to WHO
Comments:
Comparability and Interpretation: Reported treatment numbers reflect programme implementation and reporting practices within countries. Comparisons between countries should consider differences in treatment policies, eligibility criteria and health system organization.
This dataset contains a combination of country-reported data and WHO-supported modelled estimates. Values may differ because they are derived from different data sources, population coverage, reference years and methodologies. Country-reported data are intended primarily for national programme monitoring, whereas modelled estimates are intended to support standardized comparisons across countries and over time. Direct comparisons between country-reported and modelled values, or between countries represented by different observation types, should therefore be made with caution. Differences between WHO estimates and official national figures should not necessarily be interpreted as errors but may reflect methodological and data-source differences.
Treatment data may be incomplete if treatment services are delivered through multiple reporting systems or if private-sector treatment is not routinely captured. Differences in treatment eligibility criteria, reporting definitions and patient monitoring systems may affect comparability.
If you have any feedback, you are welcome to write it here.
If you need to access the old Global Health Observatory data, you can do it here. But before you leave, please provide us your feedback about our new data portal.